



July 08-10, 2024 (Hybrid) | Boston, MA

# The Global Cell & Gene Therapy Summit

**From Basic Research to CGT Products:**  
Advancing Cell and Gene Therapies through Innovation,  
Technology, and Collaboration



**Contact:**

[sanvi@cellgenetherapysummit.com](mailto:sanvi@cellgenetherapysummit.com)

[sanvi@cgtsummit.com](mailto:sanvi@cgtsummit.com)

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.com/>



# Welcome to CGT Summit 2024

We are thrilled to extend a warm welcome to all participants of the CGT Summit 2024. This summit will bring together exceptional experts from academia and industry, fostering discussions on diverse topics of cell and gene therapy. CGT Summit's comprehensive agenda will feature talks on topics ranging from genome engineering, gene regulation, and viral vector purification to precision gene therapy, cell therapy innovations, and immunotherapy advances.

CGT sessions also list talks on AI-driven decision-making, efficient process development, compliant manufacturing of iPSC-derived therapies, AAV production optimization, closed and automated manufacturing processes with regulatory considerations, public-private partnerships, clinical trial strategies, and the pivotal journey of scaling cell therapies from trials to commercialization.

With a thematic focus on "From Basic Research to CGT Products: Advancing Cell and Gene Therapies through Innovation, Technology, and Collaboration," the summit aims to have meaningful discussions and impactful networking sessions. We look forward to dynamic discussions, insightful presentations, and collaborative endeavors that will undoubtedly drive progress in the realm of cell and gene therapies.

## Contact:

[sanvi@cellgenetherapysummit.com](mailto:sanvi@cellgenetherapysummit.com)

[sanvi@cgtsummit.com](mailto:sanvi@cgtsummit.com)

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.com/>



# EXPERTS @ CGT SUMMIT 2024



Luis Pereira de Almeida  
President  
CNC UC, Portugal



Rachel Salzman  
CEO  
Armatus Bio, OH



Keiichi Fukuda  
CEO  
Heartseed,  
Japan



Deborah D. Ascheim  
Chief Medical Officer  
Rejuvenate Bio, CA



Joseph Pekny  
Co-Founder/CEO  
Advanced Process  
Combinatorics Inc., IN



Irene Rombel  
CEO & Co-  
founder  
BioCurie, DE



Daniel Getts  
Chief Executive Officer  
Myeloid Therapeutics,  
MA



Hiroshi Sugimoto  
Associate Director  
Takeda Development  
Center Americas Inc.,  
MA



Amir Hefni  
CEO  
Resolution  
Therapeutics,  
UK



Kira Gillett  
Program Manager,  
Translational Science  
FNIH, MD



Jason Criscione  
CSO  
Enquyst Technologies,  
Inc., MA



Lynne Frick  
President & CEO  
Cell X  
Technologies,  
OH



Xingxing Zang  
Louis Goldstein Swan Chair  
in Cancer Research  
Albert Einstein College  
of Medicine, NY



Larry Forman  
Founder and CEO  
CHO Plus, Inc., CA



Yuechao Zhao  
Director, R&D  
Celularity Inc.,  
NJ

## Contact:

[sanvi@cellgenetherapysummit.com](mailto:sanvi@cellgenetherapysummit.com)

[sanvi@cgtsummit.com](mailto:sanvi@cgtsummit.com)

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.com/>

# EXPERTS @ CGT SUMMIT 2024




Moritz von Stosch  
Chief Innovation Officer  
Datahow, Switzerland



Michael Chen  
CEO & Co-founder  
Great Bay Bio,  
Hong Kong



Rudolf Jaenisch  
Professor  
MIT, MA



Alan M. Lambowitz  
Professor  
The University of Texas  
at Austin, TX



Ula V. Jurkunas  
Co-director, Cornea  
Center of Excellence  
Harvard  
University, MA



Chang Li  
Assistant  
Professor  
University of  
Washington,  
WA



Victor Hernandez  
CSO  
Axovia Therapeutics Ltd  
UK



Erin Kimbrel  
President  
Astellas Institute for  
Regenerative Medicine  
MA



Michael Krohn  
Executive VP  
BRAIN Biotech  
AG, Germany



Michael Mehler  
Director  
Cell Therapy Supply  
Chain & Operations  
Takeda, MA



Jaspreet Khurana  
Senior Director  
mRNA Programming  
Strand Therapeutics,  
MA



Greg Kunst  
CEO  
Aurion Biotech,  
WA



Tetsuya Yamagata  
CSO  
Modalis Therapeutics,  
MA



Jesse Kay  
Manager  
Business Development  
PROGEN Biotech Inc.,  
AR



Demet Sag  
Founder  
Genome2Life,  
MA

## Contact:

[sanvi@cellgenetherapysummit.com](mailto:sanvi@cellgenetherapysummit.com)

[sanvi@cgtsummit.com](mailto:sanvi@cgtsummit.com)

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.com/>

# EXPERTS @ CGT SUMMIT 2024



Parameswaran Hari  
Chief Development Officer  
**Obsidian Therapeutics, MA**



Zeynep Guillemín  
Senior Scientist  
**Voyager Therapeutics, MA**



John Lu  
President & CEO  
**HebeCell, MA**



Alicia D. Henn  
CSO  
**BioSpherix, Ltd., NY**



Anand Srivastava  
Chairman & Cofounder  
**GIOSTAR, CA**



Liping Yu  
VP, Application  
**Applied Cells, CA**



Ruby Tsai  
CEO & Co-Founder  
**Applied StemCell, CA**



Asaf Hellman  
Professor  
**The Hebrew University, Israel**



Susan M. Faust  
Patent Specialist  
**Hogan Lovells US LLP, DC**



Kimberley Buytaert-Hoefen  
Executive Director & Global Head of Regulatory Affairs  
**QPS LLC, DE**



Sally Gu  
Senior Associate  
**Hogan Lovells US LLP, DC**



Hui ren Zhao  
Principal Scientist  
**Amgen, CA**



John Rossi  
Vice President/Head of Translational Medicine  
**CARGO Therapeutics, CA**



David McNally  
Head of Viral Vector Technology  
**MassBiologics, MA**




Nick Lai  
Senior Scientist  
**Regeneron Pharmaceuticals NY**

## Contact:

sanvi@cellgenetherapysummit.com  
sanvi@cgtsummit.com  
+1-469-854-2280/81, +1-844-395-4102  
Website: <https://cgtsummit.com/>



# Participants From



## Contact:

sanvi@cellgenetherapysummit.com  
sanvi@cgtsummit.com  
+1-469-854-2280/81, +1-844-395-4102  
Website: <https://cgtsummit.com/>



# Participants From



## Contact:

[sanvi@cellgenetherapysummit.com](mailto:sanvi@cellgenetherapysummit.com)

[sanvi@cgtsummit.com](mailto:sanvi@cgtsummit.com)

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.com/>



# Participants From

PROGEN



האוניברסיטה העברית בירושלים  
THE HEBREW UNIVERSITY OF JERUSALEM

B•R•A•I•N



astellas  
Institute for  
Regenerative Medicine



GIOSTAR  
GLOBAL INSTITUTE OF STEMCELL THERAPY AND RESEARCH



Applied StemCell

HebeCell MODALIS

AXOVIA  
THERAPEUTICS



OBSIDIAN  
THERAPEUTICS

MYELOID  
Therapeutics, Inc.



## Contact:

sanvi@cellgenetherapysummit.com  
sanvi@cgtsummit.com  
+1-469-854-2280/81, +1-844-395-4102  
Website: <https://cgtsummit.com/>





## Day 1, July 08, 2024

### Cell & Gene Therapy Research Advancements: Basics to Clinical Applications Gene Editing Breakthroughs and Translational Research

Track 1: Genome Engineering and Evolution

Track 2: Gene Regulation and Therapeutic Approaches

Morning Networking Break

Track 3: Precision Gene Therapy for Specific Disorders

Lunch

Track 4: Cell Therapy Innovations

Evening Networking Break

**Panel:** Next Decade of CGT Research: Future Advancements, Projections, Challenges, and Innovation

CGT Networking Drinks

## Day 2, July 09, 2024

Track 5: CGT Advances in Cancer: Precision Therapies and Immunomodulation

### Streamlining Manufacturing for Global Accessibility

Track 1: AI-Driven Decision Making in Cell & Gene Therapy Production

Morning Networking Break

Track 2: Efficient Development of CGT Processes

Track 3: Compliant Manufacturing of iPSC-Derived Therapies

Lunch

Track 4: Viral Vector Purification and Characterization

**Panel:** Collaborative Approaches: Industry-Academia Partnerships in CGT Manufacturing

Evening Networking Break

Track 5: AAV Production Process Optimization

Track 6: Closed and Automated Manufacturing Processes

## Day 3, July 10, 2024

### Regulatory Landscape and Commercialization Strategies

Track 1: Public-Private Partnerships in Cell and Gene Therapies

Morning Networking Break

Track 2: Clinical Trial Strategies for Gene Therapies

Track 3: Scaling Cell Therapies: Clinical Trials to Commercialization

Lunch

Track 4: Regulatory Considerations for Cell and Gene Therapy Products

Track 5: Preclinical Considerations for Cell and Gene Therapy Products

## **Group II Intron Reverse Transcriptases: Drivers of Genome Evolution and Tool Boxes for Genome Engineering**

**Alan M. Lambowitz**, Professor of Molecular Biosciences, The University of Texas at Austin, TX

## **MECP2. Gene Regulation and Therapeutic Approaches to Autism**

**Rudolf Jaenisch**, Professor of Biology, MIT, MA

## **The Future of Stem Cell Therapy in Ocular Disorders**

**Ula V. Jurkunas**, Co-director, Cornea Center of Excellence, Harvard University, MA

## **'Mass-Scale' Cell Therapy for Corneal Endothelial Disease**

**Greg Kunst**, CEO, Aurion Biotech, WA

## **AXV-101, a New Codon-Optimised BBS1 AAV9 Vector Halts Photoreceptor and Outer Nuclear Retinal Layer Organisation Degeneration in a Dose-dependent Manner**

**Victor Hernandez**, Chief Scientific Officer, Axovia Therapeutics Ltd, UK

## **Cis-regulatory Networks of Key Methylation Sites Describe Inter-patients Transcriptional Variation**

**Asaf Hellman**, Professor, The Hebrew University, Israel

## **Gene Therapy for Spinocerebellar Ataxia**

**Luis Pereira de Almeida**, President, CNC UC, Portugal

## **Integrated Bioanalytical Approach to Characterize the Cellular Kinetics and Biodistribution to Support Ex vivo and In vivo Gene Therapy**

**Hiroshi Sugimoto**, Associate Director, Takeda Development Center Americas Inc., MA

## **In vivo Precision Gene Therapy for Beta-hemoglobinopathies**

**Chang Li**, Assistant Professor, Medical Genetics, University of Washington, WA

## **An Overview of Stem Cell Transplant: Current Scenario in Tissue Regeneration**

**Anand Srivastava**, Chairman & Cofounder, Global Institute of Stem Cell Therapy and Research, CA

## **Innovative Approaches for Developing Pluripotent Stem Cell-based Therapies**

**Erin Kimbrel**, President, Astellas Institute for Regenerative Medicine, MA

## **Pioneering Macrophage Cell Therapy in End Stage Liver Disease**

**Amir Hefni**, CEO, Resolution Therapeutics, UK

## **ProtoNKTM Cells from Pluripotent Stem Cells: Therapeutics for All Patients**

**John Lu**, President and CEO, HebeCell, MA

## **In vivo Therapeutic Functionalities of Allogenic Mesenchymal Stromal Cells Manufactured from Human Placenta**

**Yuechao Zhao**, Director, R&D, Celularity Inc., NJ

## **Jump Start Allogenic Cell Therapies Using cGMP-Grade TARGATT Master iPSCs**

**Ruby Tsai**, CEO & Co-Founder, Applied StemCell, CA

## **Obligate Role for Rock1 and Rock2 in Adult Stem Cell Viability and Function**

**Rajita**, Senior Director Immunology Discovery, Genentech, CA

## **Epigenetic Editing with CRISPR-GNDM: Novel Muscle-tropic AAV Vectors Deliver Promising Single-dose Treatment for LAMA2-CMD**

**Tetsuya Yamagata**, CSO, Modalis Therapeutics Inc., MA

## **Advancing Liver Disease Therapies: A Perfusable Vascularized Liver Organoid-on-a-chip Model**

**Zhengpeng Wan**, Massachusetts Institute of Technology, Cambridge, MA

**TBA**

**John Rossi**, Vice President, Head of Translational Medicine, CARGO Therapeutics, CA

**TBA**

**Keiichi Fukuda**, Chief Operating Officer, Heartseed Inc., Japan

## **Regenerative Medicine Using Conserved Mechanisms for Women's Health**

**Demet (Dee) Sag**, Founder, Genome2Life, MA

## **Fine-tuning Immunity - Ex vivo siRNA Treatment to Enhance Efficiency of Cell Therapies**

**Anastasia Kremer**, University Hospital Tuebingen, Germany

## **A New Approach to Tackle Cancer Therapies Using Programmable Cytotoxic Nucleases**

**Michael Krohn**, Executive VP, Head of Research & Development, BRAIN Biotech AG, Germany

## **Programming mRNA for Cancer Immunotherapy**

**Jaspreet Khurana**, Senior Director, mRNA Programming, Strand Therapeutics, MA

## **New Immune Checkpoints: From Discoveries to Novel Drugs to Clinical Trials**

**Xingxing Zang**, Louis Goldstein Swan Chair, Albert Einstein College of Medicine, NY

## **OBX-115, an Interleukin 2 (IL2)-sparing Engineered Tumor-infiltrating Lymphocyte (TIL) Cell Therapy, in Patients (pts) with Immune Checkpoint Inhibitor (ICI)-resistant Unresectable or Metastatic Melanoma**

**Parameswaran Hari**, Chief Development Officer, Obsidian Therapeutics, MA

## **TBA**

**Daniel Getts**, CEO & Co-Founder, Myeloid Therapeutics, MA

## **Translational Development of a Novel CAR-T Cell Therapy, from Bench to Bedside**

**Yan Luo**, Assistance Professor, Mayo Clinic, FL

## **AI-Driven Decision Making for Cell & Gene Therapy Production**

**Irene Rombel**, CEO and Co-founder, BioCurie, DE

## **Resource Effective Development of CGT Processes with Hybrid Modeling and Transfer Learning**

**Moritz von Stosch**, Chief Innovation Officer, Datahow, Switzerland

## **How Pure is “Pure”? Ultra-purification of Viral Vectors**

**Jason Criscione**, Chief Scientific Officer, Enquyst Technologies, Inc., MA

## **Enabling Compliant Manufacturing of a iPSC-derived Therapies**

**Lynne Frick**, President & CEO, Cell X Technologies, OH

## **Upstream and Downstream Process Development of AAV Production Platform**

**Huiren Zhao**, Principal Scientist, Amgen, CA

## **A Novel Cell Engineering Platform for High-yield AAV Production and Improved Manufacturability**

**Larry Forman**, Founder and CEO, CHO Plus, Inc., CA

**Development and Regulatory Considerations of a Closed and Automated Manufacturing Process for TRX103, an Allogeneic, Off-the-shelf, IL-10 Engineered CD4+ T Cell Product for the Prevention of Graft-Versus-host Disease**

**James Adams**, Chief Technical Officer, Tr1X, CA

---

**TBA**

**David McNally**, Head of Viral Vector Technology, MassBiologics, MA

---

**TBA**

**Michael Chen**, CEO & Co-founder, Great Bay Bio, Hong Kong

---

**TBA**

**Joseph Pekny**, Co-founder & CEO, Advanced Process Combinatorics Inc., IN

---

**Access to an ISO5 Cell Therapy Production Space Anywhere**

**Alicia D. Henn**, CSO, BioSpherix, Ltd., NY

---

**Development of HEK293 Cell Line for Optimal Production of Novel Capsids with Enhanced Brain Tropism**

**Zeynep Guillemain**, Senior Scientist, Voyager Therapeutics, CA

---

**Lyophilization as an Effective Tool to Develop AAV8 Gene Therapy Products for Refrigerated Storage**

**Nick Lai**, Senior Scientist, Regeneron Pharmaceuticals, NY

---

**AAV Analytical Tools - Start to Finish**

**Jesse Kay**, Business Development Manager, PROGEN Biotech Inc., AR

---

**An Automated Rapid CAR T Cell Manufacturing Process on a Single Platform**

**Liping Yu**, VP Applications, Applied Cells, CA

---

## Poster Presentations

**Development of an Allogenic Cell Therapy for Parkinson's Disease Using Low-immunogenic Dopaminergic Progenitors Differentiated from Gene-edited Induced Pluripotent Stem Cells in an Experimental Animal Model**

**Chia-Ling Hsieh**, Development Center for Biotechnology, Taiwan

---

**Navigating Genetics of Dementia in the Indian Sub-continent**

**Shrutee**, Strand Life Sciences, India

---

**Aberrant Expression of TIM-4-L is a Common Feature of AML and a Potential Target for Engineered T Cell Therapy**

**Brandon Cieniewicz**, Principal Scientist, CERo Therapeutics Holdings, Inc., CA

---

**More Poster Presentations to be announced....**

**The Unknown Unknowns - New Ways of Identifying and Leveraging Stakeholders in Order to Optimally Operationalize Innovation**

**Rachel Salzman**, CEO, Armatus Bio, Inc., OH

---

**TBA**

**Kira Gillett**, Program Manager, Translational Science, FNIH, MD

---

**Clinical Trial Strategies for Gene Therapies in Rare Diseases**

**Deborah D. Ascheim**, Chief Medical Officer, Rejuvenate Bio, CA

---

**Scaling Cell Therapies - From Clinical Trials to Commercialization**

**Michael Mehler**, Director, Cell Therapy Supply Chain & Operations, MA

---

**Preclinical Considerations for Cell and Gene Therapy Products**

**Kimberley Buytaert-Hoefen**, Executive Director and Global Head of Regulatory Services, QPS Holdings, LLC, DE

---

**Maximizing Regulatory and Patent Strategy for Cell and Gene Therapy Manufacturing Success**

**Susan M. Faust**, Patent Specialist & **Sally Gu**, Life Sciences Attorney, Hogan Lovells US LLP, DC

---

**More talks will be announced soon.....**



# Collaborate with CGT Summit 2024

Calling all visionary startup founders, R&D experts, researchers, and industry leaders driving innovation in advanced manufacturing platforms, bioreactor capabilities, and other cell and gene therapy development aspects: Collaborate with CGT Summit 2024. Engage in in-depth discussions and tap into invaluable market intelligence. The summit offers abundant collaboration opportunities, industry insights, and a global perspective, providing an unparalleled platform to unlock key partnerships and explore transformative collaborations.

## Collaboration Prospects

Explore transformative partnerships for innovative cell and gene therapies

## Industry Insights

Gain crucial industry insights to propel your organization's success

## Post-Conference Resources

Get Exclusive post-conference resources for continued learning and reference after the event concludes

### Contact:

[sanvi@cellgenetherapysummit.com](mailto:sanvi@cellgenetherapysummit.com)

[sanvi@cgtsummit.com](mailto:sanvi@cgtsummit.com)

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.com/>





# Register TODAY!

[https://cgtsummit.com/registration\\_form](https://cgtsummit.com/registration_form)

## For more information:

sanvi@cellgenetherapysummit.com

sanvi@cgtsummit.com

+1-469-854-2280/81, +1-844-395-4102

## For Sponsorship and Exhibitor Opportunities:

Sponsorship Guide:

<https://cgtsummit.com/pdfs/Sponsorship-Guide.pdf>

F. Siraj

f.siraj@cellgenetherapysummit.com

+1-469-854-2280/81, +1-844-395-4102

**Contact:**

sanvi@cellgenetherapysummit.com

sanvi@cgtsummit.com

+1-469-854-2280/81, +1-844-395-4102

Website: <https://cgtsummit.com/>

